GSE117198
A Time-series transcriptome analysis of Rosiglitazone effects in mice neonatal cardiomyocytes.
Rosiglitazone is a member of the thiazolidinedione class of drugs, an anti-diabetic drug known for being a ligand of peroxisome proliferation activating receptors ? (PPAR?), a group of nuclear hormone receptors that are involved in the regulation of genes related to glucose and lipid metabolism. The use of Rosiglitazone has been shown to increase the risk of congestive heart failure in type II diabetes patients due to increased fluid retention and plasma volume. Our data show that the effects of Rosiglitazone on cardiomyocytes occur really early within a great increase in magnitude in time but consistent in the pathways affected. Also, the initial deleterious effect triggers a protective molecular response at 24 hours of exposure that is maintained at 48h but also accompanied by further activation of the system that can damage the heart. Overall design: Neonatal rat ventricular myocytes (NRVMs) were harvested from 1-day old Harlan Sprague-Dawley Rats (Rattus norvegicus albinus) and cultured as described by Sprenkle et al 1995. The cultured cells were divided In four Groups, control and exposure time of Half-hour, 24-Hours, 48-Hours.